CO [China Cord Blood] 20-F: FORM 20-F o OR x OR o For

[FORM 20-F o OR x OR o For the transition period from to OR o Date of event requiring this shell company report: China Cord Blood Corporation Cayman Islands (Jurisdiction of incorporation or organization) 48 th Floor, Bank of China Tower 1 Garden Road Central, Hong Kong S.A.R. Albert Chen +852 3605 8180 albert.chen@chinacordbloodcorp.com 48 th Floor, Bank of China] [List of Subsidiaries Name Jurisdiction China Cord Blood Services Corporation Cayman Islands China Stem Cells Holdings Limited Cayman Islands Beijing Jiachenhong Biological Technologies Co., Ltd. People’s Republic of China Guangzhou Municipality Tianhe Nuoya Bio-engineering Co., Ltd. People’s Republic of China Zhejiang Lukou Biotechnology Co., Ltd. People’s Republic of China China Stem Cells (East) Company Limited British Virgin Islands China Stem] [Certification I, Ting Zheng, certify that: 1. I have reviewed this annual report on Form 20-F of China Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [Certification I, Albert Chen, certify that: 1. I have reviewed this annual report on Form 20-F of China Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [Certification CHINA CORD BLOOD CORPORATION July 31, 2015 Ting Zheng Chief Executive Officer July 31, 2015 Albert Chen Chief Financial Officer (Principal Financial Officer) EX-13.1 5 a15-6996_1ex13d1.htm EX-13.1] [Consent of Independent Registered Public Accounting Firm The Board of Directors China Cord Blood Corporation: Hong Kong, China July 31, 2015 EX-15.1 6 a15-6996_1ex15d1.htm EX-15.1]

By | 2016-03-27T08:43:32+00:00 July 31st, 2015|Categories: Chinese Stocks, CO, Webplus ver|Tags: , , , , , |0 Comments

CO [China Cord Blood] SC 13D/A: (Original Filing)

[Execution Underwriting Agreement relating to an Open Offer of Golden Meditech Holdings Limited Golden Meditech Holdings Limited Bio Garden Inc. LEVEL 25 ONE PACIFIC PLACE 88 QUEENSWAY HONG KONG TEL: +852 2841 6888 FAX: +852 2810 0235 www.minterellison.com Table of Contents Background 3 Agreed terms 5 1.] []

By | 2016-03-27T08:44:44+00:00 July 27th, 2015|Categories: Chinese Stocks, CO, SEC Original|Tags: , , , , , |0 Comments

CO [China Cord Blood] SC 13D/A: Execution Underwriting Agreement relating to an Open Offer

[Execution Underwriting Agreement relating to an Open Offer of Golden Meditech Holdings Limited Golden Meditech Holdings Limited Bio Garden Inc. LEVEL 25 ONE PACIFIC PLACE 88 QUEENSWAY HONG KONG TEL: +852 2841 6888 FAX: +852 2810 0235 www.minterellison.com Table of Contents Background 3 Agreed terms 5 1.] []

By | 2016-03-27T08:46:03+00:00 July 27th, 2015|Categories: Chinese Stocks, CO, Webplus ver|Tags: , , , , , |0 Comments

CO [China Cord Blood] 6-K: China Cord Blood Corporation Reports Financial Results for

[China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2015 4Q15 Added 15,982 New Subscribers 4Q15 Revenue Up 7.3% YOY to RMB163.0 Million ($26.3 Million) 4Q15 Operating Income Amounted to RMB49.5 Million ($8.0 Million) Conference Call to be Held June 19, 2015 at 8:00 a.m. ET HONG KONG, China, June 18, 2015 —] [FORM 6-K For the month of June 2015 CHINA CORD BLOOD CORPORATION 48 th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R. Form 20-F x Form 40-F o o o Yes o No x EXPLANATORY NOTE Report on Report on Form 6-K are subject to risks, uncertainties and assumptions about the Company’s businesses and business environments.]

By | 2016-03-27T08:48:40+00:00 June 18th, 2015|Categories: Chinese Stocks, CO, Webplus ver|Tags: , , , , , |0 Comments

CO [China Cord Blood] 6-K: (Original Filing)

[China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2015 4Q15 Added 15,982 New Subscribers 4Q15 Revenue Up 7.3% YOY to RMB163.0 Million ($26.3 Million) 4Q15 Operating Income Amounted to RMB49.5 Million ($8.0 Million) Conference Call to be Held June 19, 2015 at 8:00 a.m. ET HONG KONG, China, June 18, 2015 —] [FORM 6-K For the month of June 2015 CHINA CORD BLOOD CORPORATION 48 th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R. Form 20-F x Form 40-F o o o Yes o No x EXPLANATORY NOTE Report on Report on Form 6-K are subject to risks, uncertainties and assumptions about the Company’s businesses and business environments.]

By | 2016-03-27T08:47:27+00:00 June 18th, 2015|Categories: Chinese Stocks, CO, SEC Original|Tags: , , , , , |0 Comments

CO [China Cord Blood] 6-K: (Original Filing)

[China Cord Blood Corporation’s Special Committee Appoints As previously announced, the Company’s board of directors formed the Special Committee to review and evaluate the April 27, 2015 non-binding proposal from Golden Meditech Holdings Limited (“Golden Meditech”) to acquire all of the outstanding ordinary shares of the Company not already directly or indirectly owned by Golden Meditech in a “going private”] [FORM 6-K Commission Filing Number: 001-34541 CHINA CORD BLOOD CORPORATION 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R. Form 20-F x Form 40-F o o o Description]

By | 2016-03-27T08:49:46+00:00 June 2nd, 2015|Categories: Chinese Stocks, CO, SEC Original|Tags: , , , , , |0 Comments

CO [China Cord Blood] 6-K: China Cord Blood Corporation’s Special Committee Appoints As

[China Cord Blood Corporation’s Special Committee Appoints As previously announced, the Company’s board of directors formed the Special Committee to review and evaluate the April 27, 2015 non-binding proposal from Golden Meditech Holdings Limited (“Golden Meditech”) to acquire all of the outstanding ordinary shares of the Company not already directly or indirectly owned by Golden Meditech in a “going private”] [FORM 6-K Commission Filing Number: 001-34541 CHINA CORD BLOOD CORPORATION 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R. Form 20-F x Form 40-F o o o Description]

By | 2016-03-27T08:51:26+00:00 June 2nd, 2015|Categories: Chinese Stocks, CO, Webplus ver|Tags: , , , , , |0 Comments

CO [China Cord Blood] 6-K: (Original Filing)

[China Cord Blood Corporation Announces Resignation of an Independent Director HONG KONG, China, May 14, 2015 — China Cord Blood Corporation (NYSE: CO) (“CCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that Mr. Julian J. Wolhardt, one of the Company’s independent directors, has resigned] [FORM 6-K Commission Filing Number: 001-34541 CHINA CORD BLOOD CORPORATION 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R. Form 20-F x Form 40-F o o o Description 99.1]

By | 2016-03-27T08:52:31+00:00 May 14th, 2015|Categories: Chinese Stocks, CO, SEC Original|Tags: , , , , , |0 Comments

CO [China Cord Blood] 6-K: China Cord Blood Corporation Announces Resignation of an

[China Cord Blood Corporation Announces Resignation of an Independent Director HONG KONG, China, May 14, 2015 — China Cord Blood Corporation (NYSE: CO) (“CCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that Mr. Julian J. Wolhardt, one of the Company’s independent directors, has resigned] [FORM 6-K Commission Filing Number: 001-34541 CHINA CORD BLOOD CORPORATION 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R. Form 20-F x Form 40-F o o o Description 99.1]

By | 2016-03-27T08:53:44+00:00 May 14th, 2015|Categories: Chinese Stocks, CO, Webplus ver|Tags: , , , , , |0 Comments
Skip to toolbar